Comparing Innovation Spending: AbbVie Inc. and Bausch Health Companies Inc.

AbbVie vs. Bausch: A Decade of R&D Investment

__timestamp	AbbVie Inc.	Bausch Health Companies Inc.
Wednesday, January 1, 2014	3297000000	246000000
Thursday, January 1, 2015	4285000000	582800000
Friday, January 1, 2016	4366000000	455000000
Sunday, January 1, 2017	4982000000	366000000
Monday, January 1, 2018	10329000000	414000000
Tuesday, January 1, 2019	6407000000	471000000
Wednesday, January 1, 2020	6557000000	452000000
Friday, January 1, 2021	7084000000	465000000
Saturday, January 1, 2022	6510000000	529000000
Sunday, January 1, 2023	8453000000	604000000

Cracking the code

Innovation Spending: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, AbbVie Inc. has consistently outpaced Bausch Health Companies Inc. in R&D investment. From 2014 to 2023, AbbVie's R&D expenses grew by approximately 156%, peaking in 2018 with a remarkable 10.3 billion dollars. In contrast, Bausch Health's R&D spending remained relatively stable, with a modest increase of about 145% over the same period, reaching its highest point in 2023.

This disparity highlights AbbVie's aggressive strategy to maintain its competitive edge through innovation, while Bausch Health adopts a more conservative approach. As the pharmaceutical sector continues to evolve, these spending patterns may significantly influence each company's future market position and product pipeline.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025